Trial · NCT02473042

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042, Not applicable, Completed, M.D. Anderson Cancer Center; results first posted 2025-12-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV). Trials, record NCT02473042. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02473042

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
NCT number: NCT02473042
Status: Completed
Phases: Not applicable
Enrollment: 188 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Post-Operative Nausea and Vomiting, Breast Cancer
Interventions: Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
First posted: 2015-06-16
Last updated: 2025-12-05
Results first posted: 2025-12-05

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day	Examine the efficacy of electrical stimulation of P6 combined with prophylactic anti-emetics versus pharmacological prophylaxis alone in preventing the incidence of PONV following breast surgery in patients at high-risk for PONV Complete control is defined as "No nausea≥3 \& No vomiting \& No use of anti-emetic during PACU stay"
Secondary	Feasibility of Conducting Study	At study consent and at PACU discharge	Determine the study feasibility where feasibility is defined by at least 20% of screened patients meeting inclusion criteria ability, 50% of these patients consenting, and 75% of patients within the acupuncture study arm completing all procedures
Secondary	Efficacy of Intervention to Prevent Need for Rescue Anti-emetics	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day	Examine the effects of intra-operative NMBM stimulation of P6 on whether or not any anti-emetics were used compared to the control group
Secondary	Satisfaction	At discharge from post-operative anesthesia care unit	Examine group differences in post-operative patient satisfaction with PONV management. Participants were asked to rate their satisfaction with their nausea and vomiting management on a scale of 0-10, where "0" equals "very dissatisfied", and "10" equals "extremely satisfied".
Secondary	Efficacy of Intervention to Result in Decreased PACU Length-of-stay	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day	Explore if intra-operative NMBM stimulation of P6 results in decreased PACU length-of-stay
Secondary	Expectancy	Baseline	Explore the associations between expectancy and response to P6 stimulation. Step 1 of 2 compares expectancy answers between groups. The expectancy questionnaire asks participants what their expectation is of the effects of the intervention on lowering their nausea after surgery, lowering their pain after surgery, enabling them to cope with nausea and/or pain better, and enabling them to have a better recovery after surgery. Possible answers are "Not at all agree", "A little agree", "Moderately agree", "Mostly agree", and "Completely agree".
Secondary	Expectancy and Response to P6 Stimulation	During stay in post-operative anesthesia care unit, until discharge	Explore the associations between expectancy and response to P6 stimulation. Step 2 of 2 compares baseline expectancy answers and response to P6 stimulation outcome directly, without taking into account group assignment. The P6 stimulation outcome was categorized as "Fail" or "Success", where "Success" is defined as "No nausea≥3 \& No vomiting \& No use of anti-emetic during PACU stay".

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Feasibility of Conducting Study	At study consent and at PACU discharge	Feasibility was defined in three different ways, and in accordance with each feasibility definition type, there was a different number of patients analyzed. Per protocol, for the completed study feasibility definition, we were only looking at the intervention arm. We were not looking at both arms.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Efficacy of Intervention to Prevent Need for Rescue Anti-emetics	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day	Number of participants analyzed does not match number of participants who completed in participant flow due to missing data	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Satisfaction	At discharge from post-operative anesthesia care unit	Number of participants analyzed does not match number of participants who completed in participant flow due to missing data	Satisfaction score	MEAN
SECONDARY	Efficacy of Intervention to Result in Decreased PACU Length-of-stay	During stay in post-operative anesthesia care unit, until discharge, an average of 1 day		number of minutes	MEAN
SECONDARY	Expectancy	Baseline		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Expectancy and Response to P6 Stimulation	During stay in post-operative anesthesia care unit, until discharge	The statistical analysis was between expectancy response at baseline and response to P6 stimulation outcome of either fail or success during PACU stay until discharge, regardless of group assignment. Number of participants analyzed does not match number of participants who completed in participant flow due to missing data for the P6 stimulation outcome.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group89

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Intervention	Fail	19	Participants
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Control	Fail	12	Participants
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Intervention	Success	67	Participants
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Control	Success	71	Participants
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Intervention	Missing Information	0	Participants
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)	Control	Missing Information	3	Participants
Feasibility of Conducting Study	Entire Study	Screened eligible	233	Participants
Feasibility of Conducting Study	Entire Study	Consented	188	Participants
Feasibility of Conducting Study	Entire Study	Completed study	86	Participants
Efficacy of Intervention to Prevent Need for Rescue Anti-emetics	Intervention	No	45	Participants

1 to 10 of 89Source ClinicalTrials.gov

See all 89 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intervention	92
Overall Study	STARTED	Control	92
Overall Study	COMPLETED	Intervention	86
Overall Study	COMPLETED	Control	86
Overall Study	NOT COMPLETED	Intervention	6
Overall Study	NOT COMPLETED	Control	6

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Muscle weakness upper limb [left]	Musculoskeletal and connective tissue disorders	Intervention	1	86
other	Muscle weakness upper limb [left]	Musculoskeletal and connective tissue disorders	Control	2	86
other	Muscle weakness upper limb [right]	Musculoskeletal and connective tissue disorders	Intervention	0	86
other	Muscle weakness upper limb [right]	Musculoskeletal and connective tissue disorders	Control	3	86
other	Numbness in left arm	Nervous system disorders	Intervention	1	86
other	Numbness in left arm	Nervous system disorders	Control	2	86
other	Numbness in right arm	Nervous system disorders	Intervention	0	86
other	Numbness in right arm	Nervous system disorders	Control	1	86
other	Pain in extremity	Musculoskeletal and connective tissue disorders	Intervention	0	86
other	Pain in extremity	Musculoskeletal and connective tissue disorders	Control	1	86

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intervention	0	86
Total, all-cause mortality	Control	0	86
Total, other adverse events	Intervention	4	86
Total, other adverse events	Control	11	86
Total, serious adverse events	Intervention	0	86
Total, serious adverse events	Control	0	86

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intervention vs Control: deaths from any cause	Trial comparisons
Intervention vs Control: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02473042

GET https://conductscience.org/api/trials/v1/NCT02473042/results?page=2

API reference For AI assistants